{"id":1780,"date":"2020-08-26T09:35:23","date_gmt":"2020-08-26T09:35:23","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/successful-beta-trial-results-for-methylation-status-detection-kit\/"},"modified":"2021-01-08T11:12:35","modified_gmt":"2021-01-08T11:12:35","slug":"successful-beta-trial-results-for-methylation-status-detection-kit","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/successful-beta-trial-results-for-methylation-status-detection-kit\/","title":{"rendered":"Successful beta trial results for methylation status detection kit"},"content":{"rendered":"<p>DNA methylation status plays an important role in an individual\u2019s disease risk and likely treatment outcome. As such it is also a necessary part of the assessments required to deliver complete personalized medicine. Now, having completed a successful beta trial, the TrueMethyl kit from Cambridge Epigenetix is a step nearer to the market. As a key part of the product validation process, 13 leading epigenetics labs were provided with the kits for independent and rigorous testing using a shared panel of control samples. The trial results demonstrate that the kit delivers a reliable and consistently high performance. The oxidative bisulfite sequencing (oxBS-Seq) technology allows quantitative, single-base resolution sequencing of the modified bases hydroxymethyl cytosine (5-hmC) and methylcytosine (5-mC), enabling accurate analysis of the DNA methylome. The kit can be used with a variety of common platforms including next generation sequencing systems, methylation arrays, and targeted assays.<\/p>\n<p><strong>Source<\/strong>: <link http:\/\/www.cambridge-epigenetix.com _blank external-link-new-window>www.cambridge-epigenetix.com<\/link>\n","protected":false},"excerpt":{"rendered":"<p>DNA methylation status plays an important role in an individual\u2019s disease risk and likely treatment outcome. As such it is also a necessary part of the assessments required to deliver complete personalized medicine. Now, having completed a successful beta trial, the TrueMethyl kit from Cambridge Epigenetix is a step nearer to the market. As a [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/1780"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=1780"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/1780\/revisions"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=1780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=1780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=1780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}